Raymond James & Associates Acquires 857 Shares of Progyny, Inc. (NASDAQ:PGNY)

Raymond James & Associates raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNYGet Rating) by 1.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 69,361 shares of the company’s stock after acquiring an additional 857 shares during the period. Raymond James & Associates’ holdings in Progyny were worth $2,571,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PGNY. Bank of New York Mellon Corp raised its position in shares of Progyny by 1.4% during the 1st quarter. Bank of New York Mellon Corp now owns 672,710 shares of the company’s stock valued at $34,579,000 after acquiring an additional 9,017 shares during the last quarter. US Bancorp DE raised its position in shares of Progyny by 92.3% during the 1st quarter. US Bancorp DE now owns 14,276 shares of the company’s stock valued at $734,000 after acquiring an additional 6,854 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Progyny by 22.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 12,296 shares of the company’s stock valued at $632,000 after acquiring an additional 2,265 shares during the last quarter. Natixis Advisors L.P. raised its position in shares of Progyny by 47.3% during the 1st quarter. Natixis Advisors L.P. now owns 29,595 shares of the company’s stock valued at $1,521,000 after acquiring an additional 9,497 shares during the last quarter. Finally, Bank of Montreal Can raised its position in shares of Progyny by 25.2% during the 1st quarter. Bank of Montreal Can now owns 7,278 shares of the company’s stock valued at $381,000 after acquiring an additional 1,465 shares during the last quarter. Institutional investors own 86.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on PGNY shares. JPMorgan Chase & Co. lowered their price objective on shares of Progyny from $78.00 to $62.00 and set an “overweight” rating for the company in a research report on Friday, November 18th. TheStreet upgraded shares of Progyny from a “d+” rating to a “c” rating in a research report on Monday, October 24th. SVB Leerink restated a “market perform” rating and issued a $34.00 price objective (down previously from $59.00) on shares of Progyny in a research report on Thursday, January 5th. Finally, KeyCorp lowered their target price on Progyny from $55.00 to $45.00 and set an “overweight” rating for the company in a report on Monday, December 19th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $49.25.

Progyny Price Performance

Progyny stock opened at $33.02 on Friday. The firm has a 50-day moving average of $32.68 and a 200-day moving average of $36.32. Progyny, Inc. has a one year low of $25.67 and a one year high of $53.10. The company has a market cap of $3.07 billion, a price-to-earnings ratio of 78.62, a P/E/G ratio of 4.25 and a beta of 1.59.

Progyny (NASDAQ:PGNYGet Rating) last posted its quarterly earnings data on Thursday, November 3rd. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.08. Progyny had a net margin of 6.00% and a return on equity of 14.14%. The company had revenue of $205.37 million during the quarter, compared to the consensus estimate of $194.41 million. As a group, sell-side analysts expect that Progyny, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Progyny

In other news, Director Norman Payson sold 6,617 shares of the stock in a transaction dated Wednesday, October 26th. The shares were sold at an average price of $41.48, for a total transaction of $274,473.16. Following the completion of the transaction, the director now directly owns 331,999 shares in the company, valued at approximately $13,771,318.52. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CFO Mark S. Livingston sold 14,801 shares of the firm’s stock in a transaction dated Tuesday, November 29th. The shares were sold at an average price of $36.70, for a total value of $543,196.70. Following the completion of the sale, the chief financial officer now directly owns 63,994 shares in the company, valued at approximately $2,348,579.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Norman Payson sold 6,617 shares of the firm’s stock in a transaction dated Wednesday, October 26th. The shares were sold at an average price of $41.48, for a total transaction of $274,473.16. Following the completion of the sale, the director now owns 331,999 shares of the company’s stock, valued at $13,771,318.52. The disclosure for this sale can be found here. Insiders sold a total of 123,966 shares of company stock worth $4,787,473 in the last three months. Insiders own 14.00% of the company’s stock.

Progyny Profile

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Read More

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNYGet Rating).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.